Exousia Pro Inc MAJI
News
-
NexTel Medical Corp. Clarifies and Expands Upon Remarks Made During Recent Online Discussion
-
NexTel Medical Corp. Executes Letter of Intent to Acquire 100% of Xycota Biosciences, LLC
-
NexTel Medical Corp. Advances Veterinary Oncology Strategy with Rollout of Early-Stage Cancer Screening for Companion Animals
Trading Information
- Previous Close Price
- $0.01
- Day Range
- $0.01–0.01
- 52-Week Range
- $0.00–0.21
- Bid/Ask
- $0.00 / $0.01
- Shares Outstanding
- 68.86M
- Market Cap
- $487,621.69
- Volume/Avg
- 178,300 / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Exousia Pro Inc is a exosome-based biotechnology, develops and manufactures mammalian and plant-based exosomes using proprietary technologies for nucleic acid loading and targeted delivery to tissues and cells. The company is developing new ways to exploit the therapeutic potential of exosomes, initially focused in the field of oncology. The platform technology of the company also helps treating a broad spectrum of viral infections.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 1
- Website
- https://www.nextelmedical.com
Valuation
|
Metric
|
MAJI
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
MAJI
|
|---|---|
Quick Ratio | 0.00 |
Current Ratio | 0.00 |
Interest Coverage | — |
Quick Ratio
MAJI
Profitability
|
Metric
|
MAJI
|
|---|---|
Return on Assets (Normalized) | — |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
MAJI
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|l@t%@y | LOCK|MJd^% | $128B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|>fNQp&k | LOCK|NXK@? | $83B | |||
| argenx SE ADR
ARGX
| LOCK|r@YDsy? | LOCK|<> | $53B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|@xt?Prz | LOCK|z&ZlF | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|$$clwT | LOCK|%l | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|>J&#d&g | LOCK|<V#! | $31B | |||
| Moderna Inc
MRNA
| LOCK|f<h!vj | LOCK|%Gg | $25B | |||
| Incyte Corp
INCY
| LOCK|#qj^wBY | LOCK|f<Q | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|L$QlM&D | LOCK|&$c | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|mkq!kSB | LOCK|xH | $16B |
United States